aTyr Pharma Inc. Common Stock (NASDAQ: ATYR)
20 Days left to seek lead plaintiff status.
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy of Efzofitimod, particularly, the drug's capability to allow a patient to completely taper their steroid usage.